Avanir To File Neurodex NDA For Pseudobulbar Affect By End Of 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will request priority review for the dextromethorphan/quinidine combination. A broad indication covering PBA (uncontrollable laughing/crying) in a range of neurological diseases is expected based on an agreement with FDA.
You may also be interested in...
Avanir Neurodex NDA Delayed By FDA Request For Additional Analyses
Agency requested new summary analyses "to better support the new electronic data submission guidelines," the company says.
Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.